KLF11 and cancer: Compared with empty vector, co-transfection with KLF11 decreased cPLA2α promoter activity in three different cancer cell lines, namely in FLO cells (66 ± 3.3%), SEG-1 (54.4 ± 5.8%), and SKGT-4 (by 45 ± 9%) (p < 0.05, Fig. 1B).